India's Cohance Lifesciences set for worst day in 3 yrs on lower Q1 profit
** Shares of Cohance Lifesciences COHA.NS decline 6.8% to 918.7 rupees; on track for biggest intraday pct drop since August 2022 ** Pharma co posts a 35% drop in first-quarter consol net profit; rev jumps ~13% but expenses are also up 22% ** About 327,000 shares traded, 1.7x the 30-day avg ** Year-to-date, stock down ~19% ** Despite Q1 results, stock rated "strong buy" on avg, median PT is 1,235 rupees (Reporting by Manvi Pant in Bengaluru) ((Manvi.Pant@thomsonreuters.com; +918447554364;))
Recent news on Cohance Lifesciences
See all newsBrief: Cohance Lifesciences Names Abhimanyu Ojha As CFO
Brief: Cohance Lifesciences Says U.S. FDA Issues Form 483 With Five Observations For Jaggaiahpet Unit In Andhra Pradesh
India's Cohance Lifesciences falls after US FDA inspection at Telangana plant
Brief: Cohance Lifesciences Says Investment Of USD 18 Million In NJ Bio And Aruka Bio
India's Cohance Lifesciences climbs on second-half growth outlook despite Q1 loss